BMS partners with drug accelerator to launch biotech
05-02-2020
Bristol-Myers Squibb to acquire Celgene in $74bn deal
03-01-2019
Roche to make $1.9bn acquisition
19-02-2018
CIPhotos / iStockphoto.com
Bristol-Myers Squibb (BMS) has agreed to pay $1.85 billion for an immuno-oncology programme.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
BMS, immuno-oncology, commercialisation, licence, cancer, biotechnology, Nekta Therapeutics,
